Malaysia: +603 2779 0098
Obesity is implicated in two-thirds of the leading causes of death from non-communicable diseases worldwide. The global market size for medical weight loss is estimated to reach $54 billion by 2030. The co-morbidities of obesity include hypertension, type 2 diabetes melitus, coronary artery disease, osteoarthritis, sleep apnea, cancer, and NASH. The treatment of obesity is the cornerstone of treating NASH and the co-morbidities of NASH. The recent success of Wegovy ® (semaglutide 2.4 mg), a GLP-1 monotherapy, has created a regulatory pathway for incretin-based approaches. Numerous agents have been added to GLP-1 to achieve weight loss approaching bariatric surgery.
Only products with same currency can be added to the basket. Clear the basket or finish the order, before adding products with another currency to the basket.
